A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation
NCT ID: NCT04269876
Last Updated: 2023-01-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
NA
Total Enrollment
8 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-10-31
Study Completion Date
2021-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To assess the efficacy and safety of a Marine Lipid Oil Concentrate formulation on inflammatory biomarkers and overall well-being in male and female subjects who are overweight to mildly obese, but otherwise generally healthy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation/Discomfort
NCT04819646
Inflammation
COMPLETED
NA
To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL
NCT04317287
Oxidized Low Density Lipoprotein
TERMINATED
NA
Health Benefits of Functional Oil (Mega 3 Fatty Acids From Fish Oil) on Obese People
NCT01739998
Obesity
COMPLETED
PHASE4
Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation
NCT01813110
Inflammatory Responses
COMPLETED
NA
Effects of Nutritional Intervention With Fish-derived Lipids in Improving Antiviral Immunity
NCT05502172
Nutrition, Healthy
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a double-blind randomized, placebo-controlled study to evaluate the effects of a Marine Lipid Oil Concentrate formulation on inflammation.. Each subject will receive a specific dose of the study product (A) to be taken once daily with a specific dose of the study product (B) to be taken once daily for a total of 60 days.
Participants will receive questionnaires, assessments, blood tests, vital signs and a body composition analysis.
The primary objective is the assessment of the change in the blood levels of hs-CRP in response to the Marine Lipid Oil Concentrate formulation relative to screening/baseline compared to placebo.
The secondary objective is the assessment of the change in the in response to the Marine Lipid Oil Concentrate formulation relative to screening/baseline compared to placebo for Interleukin-6 (IL-6), Tumor necrosis factor (TNF-alpha), Erythrocyte Sedimentation Rate (ESR), Fibrinogen Activity, B-type natriuretic peptide (BNP), Ferritin, Blood lipid levels (Total Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides), Short Form-36 (SF-36) Health Survey scores and the Medical Symptoms Questionnaire
Participants will receive questionnaires, assessments, blood tests, vital signs and a body composition analysis.
The primary objective is the assessment of the change in the blood levels of hs-CRP in response to the Marine Lipid Oil Concentrate formulation relative to screening/baseline compared to placebo.
The secondary objective is the assessment of the change in the in response to the Marine Lipid Oil Concentrate formulation relative to screening/baseline compared to placebo for Interleukin-6 (IL-6), Tumor necrosis factor (TNF-alpha), Erythrocyte Sedimentation Rate (ESR), Fibrinogen Activity, B-type natriuretic peptide (BNP), Ferritin, Blood lipid levels (Total Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides), Short Form-36 (SF-36) Health Survey scores and the Medical Symptoms Questionnaire
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Inflammation
Inflammatory Response
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Marine Lipid Oil concentrate
Dietary Supplement: Marine Lipid oil concentrate softgel and dietary supplement capsules
Group Type
EXPERIMENTAL
Marine Lipid Oil Concentrate
Intervention Type
DIETARY_SUPPLEMENT
Marine Lipid Oil Concentrate softgels
Dietary Supplement
Intervention Type
DIETARY_SUPPLEMENT
Dietary Supplement capsules
Placebo
Placebo softgels with Placebo capsules
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Placebo softgels
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Placebo capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Marine Lipid Oil Concentrate
Marine Lipid Oil Concentrate softgels
Intervention Type
DIETARY_SUPPLEMENT
Dietary Supplement
Dietary Supplement capsules
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Placebo softgels
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Placebo capsules
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Ambulatory, male or female, 35-75 years of age
2. A BMI of 23-34.9
3. hs-CRP level of 1-7.5 mg/L
4. Generally healthy and having no significant difficulty with digestion or absorption of food
5. Has been generally weight stable for the past six months (+/- 6 lbs.)
6. Willing and able to give written informed consent
7. Clearly understands the procedures and study requirements
8. Willing and able to comply with all study procedures, including following the recommendations to maintain their usual diet and regular activity, as per protocol
9. Able to communicate, including reading, in English
10. Have not taken any nutritional supplements that may contain any of the components of the study product for a minimum of 14 days before Screening/baseline
2. A BMI of 23-34.9
3. hs-CRP level of 1-7.5 mg/L
4. Generally healthy and having no significant difficulty with digestion or absorption of food
5. Has been generally weight stable for the past six months (+/- 6 lbs.)
6. Willing and able to give written informed consent
7. Clearly understands the procedures and study requirements
8. Willing and able to comply with all study procedures, including following the recommendations to maintain their usual diet and regular activity, as per protocol
9. Able to communicate, including reading, in English
10. Have not taken any nutritional supplements that may contain any of the components of the study product for a minimum of 14 days before Screening/baseline
Exclusion Criteria
1. Having smoked any cigarette, electronic cigarette, cigar, pipe, or used a recreational drug as well as any product containing cannabidiol (CBD) and tetrahydrocannabinol in the past 30 days.
2. Donated blood within 30 days before Screening/baseline
3. Inability to provide a venous blood sample
4. Participation in another study within 30 days before Screening/baseline
5. Being pregnant or planning on becoming pregnant during study participation; or breast feeding
6. History of allergy or sensitivity to any component of the study products
7. Currently taking a lipid lowering medication or dietary supplement
8. Currently taking a medication or dietary supplement specifically for pain or inflammation including curcumin and unwilling to washout (i.e., stop taking) for 14 days before Screening/baseline
9. Currently taking or having taken a fish oil, krill oil, omega-3 supplement and omega-3 prescription drugs within the past 3 months before Screening/baseline
10. Currently taking or having taken pain medications or anti-inflammatory medication(s) (e.g., aspirin, NSAIDs, Cyclooxygenase-2 (COX-2) inhibitors, and corticosteroids) within 14 days before Screening/baseline or in the judgment of the Study Investigator/Sub-I would not preclude participation in the study
11. Having been diagnosed, received medical treatment, or taking medication daily for the following medical condition(s):
* Acute or chronic inflammatory or autoimmune disease (including rheumatoid arthritis, system lupus erythematosus, ankylosing spondylitis, Sjögren's syndrome, polymyalgia rheumatica, inflammatory bowel disease, and psoriatic arthritis)
12. Presence of active or recurring clinically significant conditions as follows:
* Diabetes mellitus or other endocrine disease
* Acute infection
* Active periodontal disease
* Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke, or heart valve problem
* Gastrointestinal disease including gallbladder problems, gallstones, or biliary tract obstruction
* Thyroid disease (unless on a stable dose of medication for 3 months before screening and unlikely to change medication or dose during the study)
* Hypertension (unless on a stable dose of medication for 3 months screening and unlikely to change medication or dose during the study)
* Neurologic condition/disease
* Cancer (unless skin cancer other than melanoma which has been treated \> 3 years before Screening/baseline)
* Liver, pancreatic, and kidney disease
* Pulmonary disease
* Blood coagulation disorder or other hematologic disease
* Other condition or medication use that would preclude participation in the study in the judgment of the Investigator/Sub-I
13. Currently taking any medications or treatment for a psychiatric disorder (bipolar disorder,manic disorder, schizophrenia, apathetic \[inherited\] disorder), that include antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants; benzodiazepines; central nervous system (CNS) depressants, dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs); pentazocine, phenothiazines, and tramadol. These may preclude participation in the study dependent on the judgment of the Investigator/Sub-I.
14. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including dehydroepiandrosterone (DHEA), estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for \> 3 months, with no anticipated change for the duration of the study)
15. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-I, would preclude participation in the study
16. Having abnormal screening laboratory test values including bilirubin \> 2.5 x upper limit of normal (ULN), aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine transaminase (ALT)/serum glutamic-pyruvic transaminase (SGPT) \> 2.5 x ULN, serum creatinine \> 1.5 mg/dL, blood glucose \< 85 mg/dL or \> 110 mg/dL, hs-CRP \< 1.0 mg/L or \> 5 mg/L, or other lab test result(s) that would preclude study participation in the judgement of the Study Investigator/Sub-I
17. Having blood pressure readings at Screening/baseline \> 140 systolic or \> 90 diastolic on two consecutive readings unless permitted to proceed to the next visit in the judgment of the Study Investigator/Sub-I
18. Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
19. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos
20. History of known or suspected substance abuse (e.g., alcohol, opiates, benzodiazepines or amphetamines).
21. Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-I, including use of other nutritional supplements, which will be evaluated on a case-by-case basis.
2. Donated blood within 30 days before Screening/baseline
3. Inability to provide a venous blood sample
4. Participation in another study within 30 days before Screening/baseline
5. Being pregnant or planning on becoming pregnant during study participation; or breast feeding
6. History of allergy or sensitivity to any component of the study products
7. Currently taking a lipid lowering medication or dietary supplement
8. Currently taking a medication or dietary supplement specifically for pain or inflammation including curcumin and unwilling to washout (i.e., stop taking) for 14 days before Screening/baseline
9. Currently taking or having taken a fish oil, krill oil, omega-3 supplement and omega-3 prescription drugs within the past 3 months before Screening/baseline
10. Currently taking or having taken pain medications or anti-inflammatory medication(s) (e.g., aspirin, NSAIDs, Cyclooxygenase-2 (COX-2) inhibitors, and corticosteroids) within 14 days before Screening/baseline or in the judgment of the Study Investigator/Sub-I would not preclude participation in the study
11. Having been diagnosed, received medical treatment, or taking medication daily for the following medical condition(s):
* Acute or chronic inflammatory or autoimmune disease (including rheumatoid arthritis, system lupus erythematosus, ankylosing spondylitis, Sjögren's syndrome, polymyalgia rheumatica, inflammatory bowel disease, and psoriatic arthritis)
12. Presence of active or recurring clinically significant conditions as follows:
* Diabetes mellitus or other endocrine disease
* Acute infection
* Active periodontal disease
* Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke, or heart valve problem
* Gastrointestinal disease including gallbladder problems, gallstones, or biliary tract obstruction
* Thyroid disease (unless on a stable dose of medication for 3 months before screening and unlikely to change medication or dose during the study)
* Hypertension (unless on a stable dose of medication for 3 months screening and unlikely to change medication or dose during the study)
* Neurologic condition/disease
* Cancer (unless skin cancer other than melanoma which has been treated \> 3 years before Screening/baseline)
* Liver, pancreatic, and kidney disease
* Pulmonary disease
* Blood coagulation disorder or other hematologic disease
* Other condition or medication use that would preclude participation in the study in the judgment of the Investigator/Sub-I
13. Currently taking any medications or treatment for a psychiatric disorder (bipolar disorder,manic disorder, schizophrenia, apathetic \[inherited\] disorder), that include antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants; benzodiazepines; central nervous system (CNS) depressants, dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs); pentazocine, phenothiazines, and tramadol. These may preclude participation in the study dependent on the judgment of the Investigator/Sub-I.
14. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including dehydroepiandrosterone (DHEA), estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for \> 3 months, with no anticipated change for the duration of the study)
15. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-I, would preclude participation in the study
16. Having abnormal screening laboratory test values including bilirubin \> 2.5 x upper limit of normal (ULN), aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine transaminase (ALT)/serum glutamic-pyruvic transaminase (SGPT) \> 2.5 x ULN, serum creatinine \> 1.5 mg/dL, blood glucose \< 85 mg/dL or \> 110 mg/dL, hs-CRP \< 1.0 mg/L or \> 5 mg/L, or other lab test result(s) that would preclude study participation in the judgement of the Study Investigator/Sub-I
17. Having blood pressure readings at Screening/baseline \> 140 systolic or \> 90 diastolic on two consecutive readings unless permitted to proceed to the next visit in the judgment of the Study Investigator/Sub-I
18. Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
19. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos
20. History of known or suspected substance abuse (e.g., alcohol, opiates, benzodiazepines or amphetamines).
21. Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-I, including use of other nutritional supplements, which will be evaluated on a case-by-case basis.
Minimum Eligible Age
35 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Supplement Formulators, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Swick, Ph.D
Role: PRINCIPAL_INVESTIGATOR
LIfe Extension
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lfie Extension Clinical Reseach, Inc.
Fort Lauderdale, Florida, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013 Aug;169(8):1672-92. doi: 10.1111/bph.12131.
Reference Type
BACKGROUND
Bassiouny AR, Zaky A, Kandeel KM. Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats. Ann Hepatol. 2011 Oct-Dec;10(4):516-30.
Reference Type
BACKGROUND
Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, Montaseri A, Shakibaei M. Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2011 Aug 12;286(32):28556-66. doi: 10.1074/jbc.M111.256180. Epub 2011 Jun 13.
Reference Type
BACKGROUND
Campbell, M., Berrones, A., Krishnakumar, I. M., Charnigo, R. J., Westgate, P. M., & Fleenor, B. S. (2017). Responsiveness to curcumin intervention is associated with reduced aortic stiffness in young, obese men with higher initial stiffness. J Funct Foods, 29, 154-160.
Reference Type
BACKGROUND
Campbell MS, Ouyang A, I M K, Charnigo RJ, Westgate PM, Fleenor BS. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial. Nutrition. 2019 Jun;62:135-139. doi: 10.1016/j.nut.2019.01.002. Epub 2019 Jan 11.
Reference Type
BACKGROUND
Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S Jr. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol. 2012 May;66(5):752-60. doi: 10.1016/j.jaad.2011.04.022. Epub 2011 Sep 9.
Reference Type
BACKGROUND
Chen FY, Zhou J, Guo N, Ma WG, Huang X, Wang H, Yuan ZY. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun. 2015 Nov 27;467(4):872-8. doi: 10.1016/j.bbrc.2015.10.051. Epub 2015 Oct 19.
Reference Type
BACKGROUND
Dallal, G (2017). Randomization.com. Retrieved from http://www.randomization.com
Reference Type
BACKGROUND
Doyle R, Sadlier DM, Godson C. Pro-resolving lipid mediators: Agents of anti-ageing? Semin Immunol. 2018 Dec;40:36-48. doi: 10.1016/j.smim.2018.09.002. Epub 2018 Oct 4.
Reference Type
BACKGROUND
Fiala M, Terrando N, Dalli J. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-beta Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment. J Alzheimers Dis. 2016;49(4):1191. doi: 10.3233/JAD-159008. No abstract available.
Reference Type
BACKGROUND
Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017 Oct 22;6(10):92. doi: 10.3390/foods6100092.
Reference Type
BACKGROUND
Krishnakumar, I, Abhilash, M., Gopakumar, G.,et al. Improved blood-brain-barrier permeability and tissue distribution following the oral administration of a food-grade formulation of curcumin with fenugreek fibre. J. Funct Foods, 14, 215-225
Reference Type
BACKGROUND
T Krishnareddy N, Thomas JV, Nair SS, N Mulakal J, Maliakel BP, Krishnakumar IM. A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study. Biomed Res Int. 2018 Sep 23;2018:9159281. doi: 10.1155/2018/9159281. eCollection 2018.
Reference Type
BACKGROUND
Kumar, D., Jacob, D., Subash. P. et al. (2016). Enhanced bioavailability and relative distribution of free (unconjugated) curcuminoids following the oral administration of a food-grade formulation with fenugreek dietary fibre: A randomised double-blind crossover study. J Funt Foods, 22, 578-587
Reference Type
BACKGROUND
Lopez-Vicario C, Rius B, Alcaraz-Quiles J, Garcia-Alonso V, Lopategi A, Titos E, Claria J. Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. Eur J Pharmacol. 2016 Aug 15;785:133-143. doi: 10.1016/j.ejphar.2015.03.092. Epub 2015 May 15.
Reference Type
BACKGROUND
Madhu K, Chanda K, Saji MJ. Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology. 2013 Apr;21(2):129-36. doi: 10.1007/s10787-012-0163-3. Epub 2012 Dec 16.
Reference Type
BACKGROUND
Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant. 2006 Jul;25(7):834-8. doi: 10.1016/j.healun.2006.03.005. Epub 2006 May 24.
Reference Type
BACKGROUND
Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105-25. doi: 10.1007/978-0-387-46401-5_3.
Reference Type
BACKGROUND
Nathan C, Ding A. Nonresolving inflammation. Cell. 2010 Mar 19;140(6):871-82. doi: 10.1016/j.cell.2010.02.029.
Reference Type
BACKGROUND
Nordgren TM, Anderson Berry A, Van Ormer M, Zoucha S, Elliott E, Johnson R, McGinn E, Cave C, Rilett K, Weishaar K, Maddipati SS, Appeah H, Hanson C. Omega-3 Fatty Acid Supplementation, Pro-Resolving Mediators, and Clinical Outcomes in Maternal-Infant Pairs. Nutrients. 2019 Jan 5;11(1):98. doi: 10.3390/nu11010098.
Reference Type
BACKGROUND
Norling LV, Ly L, Dalli J. Resolving inflammation by using nutrition therapy: roles for specialized proresolving mediators. Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):145-152. doi: 10.1097/MCO.0000000000000353.
Reference Type
BACKGROUND
Norris PC, Skulas-Ray AC, Riley I, Richter CK, Kris-Etherton PM, Jensen GL, Serhan CN, Maddipati KR. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. Sci Rep. 2018 Dec 21;8(1):18050. doi: 10.1038/s41598-018-36679-4.
Reference Type
BACKGROUND
Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, Sahebkar A. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. 2016 Aug;82:578-82. doi: 10.1016/j.biopha.2016.05.037. Epub 2016 Jun 6.
Reference Type
BACKGROUND
Pandaran Sudheeran S, Jacob D, Natinga Mulakal J, Gopinathan Nair G, Maliakel A, Maliakel B, Kuttan R, Im K. Safety, Tolerance, and Enhanced Efficacy of a Bioavailable Formulation of Curcumin With Fenugreek Dietary Fiber on Occupational Stress: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. J Clin Psychopharmacol. 2016 Jun;36(3):236-43. doi: 10.1097/JCP.0000000000000508.
Reference Type
BACKGROUND
Saji S, Asha S, Svenia PJ, Ratheesh M, Sheethal S, Sandya S, Krishnakumar IM. Curcumin-galactomannoside complex inhibits pathogenesis in Ox-LDL-challenged human peripheral blood mononuclear cells. Inflammopharmacology. 2018 Oct;26(5):1273-1282. doi: 10.1007/s10787-018-0474-0. Epub 2018 Apr 9.
Reference Type
BACKGROUND
Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. 2017 Dec;58:1-11. doi: 10.1016/j.mam.2017.03.001. Epub 2017 Mar 3.
Reference Type
BACKGROUND
So J, Wu D, Lichtenstein AH, Tai AK, Matthan NR, Maddipati KR, Lamon-Fava S. EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study. Atherosclerosis. 2021 Jan;316:90-98. doi: 10.1016/j.atherosclerosis.2020.11.018. Epub 2020 Dec 7.
Reference Type
BACKGROUND
Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014 Jan 7;19(1):21-36. doi: 10.1016/j.cmet.2013.10.006. Epub 2013 Nov 14.
Reference Type
BACKGROUND
Wongcharoen W, Jai-Aue S, Phrommintikul A, Nawarawong W, Woragidpoonpol S, Tepsuwan T, Sukonthasarn A, Apaijai N, Chattipakorn N. Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting. Am J Cardiol. 2012 Jul 1;110(1):40-4. doi: 10.1016/j.amjcard.2012.02.043. Epub 2012 Apr 3.
Reference Type
BACKGROUND
Yu Y, Shen Q, Lai Y, Park SY, Ou X, Lin D, Jin M, Zhang W. Anti-inflammatory Effects of Curcumin in Microglial Cells. Front Pharmacol. 2018 Apr 20;9:386. doi: 10.3389/fphar.2018.00386. eCollection 2018.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Human In Vivo Feeding Study Of The Blood Monocyte Response To Dietary Lipid Intake
NCT02101346
TERMINATED
NA
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
NCT05161702
RECRUITING
Effect of Palmitoleic Acid on C-reactive Protein
NCT03625427
COMPLETED
NA
Effects of Dietary Fatty Acids on Octadecanoid Production and Biological Actions in Obesity-induced Inflammation
NCT03583281
COMPLETED
NA
Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -
NCT04647604
COMPLETED
PHASE2
Explore Effects of Dietary Fish Oil in Human Skin
NCT03122912
TERMINATED
PHASE1
Omega-3 Fatty Acid Supplementation in Older Adults
NCT01666392
WITHDRAWN
NA
Maqui Berry Extract and Omega-3 Fatty Acids for Cytokine Reduction
NCT04914312
COMPLETED
NA
Effects of Omega-3 Fatty Acids on Markers of Inflammation
NCT01129050
COMPLETED
NA
Fish Oil and Inflammation in Overweight Subjects
NCT00885053
COMPLETED
NA
SPM Regulation by Fish Oil Supplements in Healthy Volunteers
NCT03347006
COMPLETED
NA
Omega-3 Supplementation and Resistance Training
NCT02617511
COMPLETED
NA
Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels
NCT00578578
TERMINATED
PHASE4
Transcriptomics of Mononuclear Cells and Inflammatory Status of Obese Patients Treated With Omega-3 Fatty Acids
NCT05219890
WITHDRAWN
NA
Omega-3 Supplement and Health Markers
NCT06492694
COMPLETED
NA
Omega 7 Oil and Inflammatory Biomarker Study
NCT03669575
COMPLETED
NA
Omega 7 + 3 Combination and Systemic Inflammation
NCT02155816
COMPLETED
NA
Effect of a Mediterranean Diet and Omega-3 Fatty Acids on Oxidative Stress and Endothelial Progenitor Cells (EPC's)
NCT00166088
COMPLETED
PHASE2
Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation
NCT03210805
UNKNOWN
NA
Effect of Plant Omega-3 and Omega-6 Fatty Acids on Exercise Performance
NCT02654392
UNKNOWN
NA
Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus
NCT02629497
COMPLETED
EARLY_PHASE1
OEA for Targeting Lipid Metabolism in GWI
NCT05252949
COMPLETED
NA
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
NCT00504309
COMPLETED
NA
Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients
NCT01477697
TERMINATED
PHASE1/PHASE2